Does adding a virtual reality self-management stress-reduction tool (VRelax) to treatment as usual (TAU) reduce psychiatric symptoms, medication use, improve psychosocial functioning and reduce costs in patients with anxiety, depressive, bipolar or psychotic disorder when compared to TAU only, and what are the barriers and facilitators for implementation of VRelax in healthcare?
Adding VRelax to TAU reduces psychiatric symptoms, medication use and improves psychosocial functioning at a lower cost than TAU.
Multi-center randomized controlled trial.
Patients with anxiety, depressive, bipolar or psychotic disorder.
VRelax: VR 360 degree videos of calm natural environments with interactive stress-reducing elements in addition to TAU. The intervention will be adjusted for the purpose of this study and improved iteratively in collaboration with a user panel consisting of patients and healthcare providers before the trial commences.
TAU: Treatment following national guidelines.
Primary: psychiatric symptoms
Secondary: medication use, psychosocial functioning, substance use, stress, sleep, costs, physiological outcomes, process evaluations
In-depth patient interviews.
185 participants, intention to treat, mixed-effects regression analyses.